Gadodiamide

Gadodiamide is a gadolinium-based MRI contrast agent, used in MR imaging procedures to assist in the visualization of blood vessels. It is commonly marketed under the trade name Omniscan.

Gadodiamide

Clinical data
Other names	2-[bis[2-(carboxylatomethyl-(methylcarbamoylmethyl)amino)ethyl]amino]acetate; gadolinium(+3) cation
AHFS/Drugs.com	Micromedex Detailed Consumer Information
Routes of administration	Intravenous
ATC code	V08CA03 (WHO)
Legal status
Legal status	US: ℞-only EU: Rx-only [1]
Pharmacokinetic data
Protein binding	negligible
Metabolism	not metabolized
Elimination half-life	77.8 minutes
Excretion	Kidney
Identifiers
IUPAC name gadolinium(III) 5,8-bis(carboxylatomethyl)-2-[2-(methylamino)-2-oxoethyl]-10-oxo-2,5,8,11-tetraazadodecane-1-carboxylate hydrate
CAS Number	131410-48-5 122795-43-1 (hydrate)
PubChem CID	153921
DrugBank	DB00225
ChemSpider	135661
UNII	84F6U3J2R6
KEGG	D01645
ChEBI	CHEBI:37333
ChEMBL	ChEMBL1200346
CompTox Dashboard (EPA)	DTXSID9048647
Chemical and physical data
Formula	C16H28GdN5O9
Molar mass	591.68 g·mol^−1
3D model (JSmol)	Interactive image
SMILES [Gd+3].[O-]C(=O)CN(CC(=O)NC)CCN(CCN(CC([O-])=O)CC(=O)NC)CC([O-])=O
InChI InChI=1S/C16H29N5O8.Gd/c1-17-12(22)7-20(10-15(26)27)5-3-19(9-14(24)25)4-6-21(11-16(28)29)8-13(23)18-2;/h3-11H2,1-2H3,(H,17,22)(H,18,23)(H,24,25)(H,26,27)(H,28,29);/q;+3/p-3 Key:HZHFFEYYPYZMNU-UHFFFAOYSA-K
(what is this?)  (verify)

Uses

A bottle of Omniscan contrast agent.

Gadodiamide is a drug i.e contrast medium used for cranial and spinal magnetic resonance imaging (MRI) and for general MRI of the body after intravenous administration. The product provides contrast enhancement and facilitates visualisation of abnormal structures or lesions in various parts of the body including the central nervous system (CNS). It does not cross an intact blood brain barrier but might give enhancement in pathological conditions.

Adverse effects

It has been associated with a toxic reaction known as nephrogenic systemic fibrosis (NSF) in some people with severe kidney problems.[2] No cases have been seen in people with normal kidney function.[3]

A 2015 study found trace amounts of gadolinium deposited in the brain tissue of people that had received gadodiamide.[4] This is of unknown significance.[4]

In the United States there are recommendations that one does not need to stop or altering breastfeeding while in Europe it is recommended that a mother throw out 24 hours of breast milk.[5]

References

1. https://www.ema.europa.eu/documents/psusa/gadodiamide-list-nationally-authorised-medicinal-products-psusa/00001503/202004_en.pdf
2. Ibrahim MA, Hazhirkarzar B, Dublin AB (January 2018). "Magnetic Resonance Imaging (MRI), Gadolinium". StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing. PMID 29494094.
3. Canavese C, Mereu MC, Aime S, Lazzarich E, Fenoglio R, Quaglia M, Stratta P (2008). "Gadolinium-associated nephrogenic systemic fibrosis: the need for nephrologists' awareness". Journal of Nephrology. 21 (3): 324–36. PMID 18587720.
4. Anderson P (2015-03-26). "Gadolinium Found in Brain Tissue". Medscape. Retrieved 14 April 2015.
5. "Gadodiamide". Drugs and Lactation Database. 2006. PMID 30000472.